Evidence map›Paper›PMID 26804815›Full record

ReviewThe ocular surface2016

Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System.

Vivien J Coulson-Thomas, Yvette M Coulson-Thomas, Tarsis F Gesteira, Winston W-Y Kao

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The ocular surface, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05204329 (Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05204329 early_phase1completednot on this mapstarted 2024, after this paper: background citation

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2024 to 2024Enrolled9ConditionsMesenchymal Stromal Cells, Cornea, Corneal Defect, Corneal Epithelium DefectArmsMSC Secretome Eye Drops
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Facts and Hopes in Multiple Myeloma Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Vivien J Coulson-ThomasDepartment of Ophthalmology, University of Cincinnati, Ohio, USA; John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK. Electronic address: vcoulsonthomas@gmail.com.
Yvette M Coulson-ThomasDepartamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Tarsis F GesteiraDepartment of Ophthalmology, University of Cincinnati, Ohio, USA.
Winston W-Y KaoDepartment of Ophthalmology, University of Cincinnati, Ohio, USA. Electronic address: winston.kao@uc.edu.
University of Cincinnati · USUniversidade Federal de São Paulo · BRUniversity of Cambridge · GB

Funding

Structure/Function Relationship of The Lumican GeneR01EY011845 · NEI · UNIVERSITY OF CINCINNATI · PI KAO, WINSTON W · 1999 to 2017
$5.2M
Cell Therapy of Corneal Diseases with Umbilical Mesenchymal Stem CellsR01EY021768 · NEI · UNIVERSITY OF CINCINNATI · PI KAO, WINSTON W · 2011 to 2014
$2.2M
NEI NIH HHS R01 EY011845NEI NIH HHS R01 EY021768
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are a group of fibroblast-like multipotent mesenchymal stromal cells that have the ability to differentiate into osteoblasts, adipocytes, and chondrocytes. Recent studies have demonstrated that MSCs possess a unique ability to exert suppressive and regulatory effects on both adaptive and innate immunity in an autologous and allogeneic manner. A vital step in stem cell transplantation is overcoming the potential graft-versus-host disease, which is a limiting factor to transplantation success. Given that MSCs attain powerful differentiation capabilities and also present immunosuppressive properties, which enable them to survive host immune rejection, MSCs are of great interest. Due to their ability to differentiate into different cell types and to suppress and modulate the immune system, MSCs are being developed for treating a plethora of diseases, including immune disorders. Moreover, in recent years, MSCs have been genetically engineered to treat and sometimes even cure some diseases, and the use of MSCs for cell therapy presents new perspectives for overcoming tissue rejection. In this review, we discuss the potential extrinsic and intrinsic mechanisms that underlie MSCs' unique ability to modulate inflammation, and both innate and adaptive immunity.

Indexed as

Mesenchymal Stem CellsCell DifferentiationHumansImmune SystemMesenchymal Stem Cell Transplantationgraft versus host diseaseimmunityinflammationmesenchymal stem cellsstem cell transplantation

Identifiers

PMID26804815
PMCPMC4842329
OpenAlexW2293666953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.